BBOT BBO-11818: $648M pan-KRAS vs RVMD $40B

KRAS is the most frequently mutated oncogene in human cancer, driving roughly 23% of all adult solid tumors. For 40 years it was called “undruggable.” Then Amgen cracked the G12C mutation with Lumakras, a narrow target that covers just 15% of KRAS-mutant cancers. The real prize is pan-KRAS: a single pill that hits G12D, G12V, G12R, G12C, and every other variant. BridgeBio Oncology Therapeutics (BBOT) is one of three companies racing to deliver it, and its BBO-11818 Phase 1 data is due in the second half of 2026.

At $8.09 per share, BBOT carries a $648 million market cap. Revolution Medicines (RVMD), the pan-RAS leader, trades at $187.53 with a $39.9 billion market cap. That 61x gap is the trade.

Why pan-KRAS matters more than G12C

The G12C mutation dominates non-small cell lung cancer (NSCLC), accounting for 40% of KRAS-mutant non-squamous NSCLC. Amgen’s Lumakras and Merck’s Krazati both target G12C exclusively. But G12C is only 15% of the pan-cancer KRAS picture. The largest variants are G12D (29% of KRAS mutations) and G12V (23%), which dominate pancreatic and colorectal cancer.

In pancreatic ductal adenocarcinoma (PDAC), where 93% of tumors harbor a KRAS mutation, G12D accounts for 43.6% of mutations and G12V for 30.8%. G12C appears in just 1.6% of PDAC cases. A G12C-only inhibitor is commercially irrelevant in the deadliest KRAS-driven cancer. The company that delivers a true pan-KRAS inhibitor addresses a $5 to $15 billion peak sales opportunity, compared to Lumakras’ $363 million in 2025 revenue growing at 4% annually.

BBO-11818: mechanism and trial design

BBO-11818 is an orally bioavailable, non-covalent pan-KRAS inhibitor that binds both the ON (GTP-bound) and OFF (GDP-bound) states of KRAS. It is highly selective for KRAS over HRAS and NRAS, which matters for the toxicity profile. The drug is being evaluated in the Phase 1 KONQUER-101 trial (NCT06917079), an open-label, multi-center study enrolling patients with locally advanced unresectable or metastatic KRAS-mutant solid tumors.

The trial design is ambitious. KONQUER-101 has 10 dose-escalation cohorts in Phase 1a, spanning monotherapy and combinations with pembrolizumab, cetuximab, chemotherapy backbones (mFOLFOX6, mFOLFIRINOX, gemcitabine plus nab-paclitaxel), and a companion molecule BBO-10203 (a PI3K-alpha inhibitor). This is not a minimal Phase 1. BBOT is building the combination matrix for a registrational program from day one.

Preclinical data presented at AACR 2026 showed the following: a single 100 mg/kg oral dose reduced pERK tumor levels by 85% at 6 hours, with an in vivo EC50 of 138 nmol/L consistent with the free-fraction-adjusted in vitro IC50 of 149 nmol/L. The drug achieves target engagement at oral doses that are clinically achievable.

What the Phase 1 data needs to show

Preliminary data released January 7, 2026 (data cutoff December 10, 2025) already showed a confirmed partial response in a pancreatic cancer patient with a 56% tumor reduction. Anti-tumor activity was observed across dose levels and tumor types, with tumor reductions at higher dose levels. Critically, BBO-11818 monotherapy showed no dose-limiting toxicities (DLTs) and approximately dose-proportional exposure at 600 mg twice daily, covering the G12D and G12V alleles.

The FDA granted Fast Track Designation on April 20, 2026 for advanced KRAS-mutant PDAC, based on that preliminary signal.

The updated H2 2026 readout needs to answer three questions. First, does the safety profile hold as the dose escalates and more patients enroll? Pan-KRAS inhibitors carry inherent toxicity risk because they inhibit wild-type RAS to some degree. Second, does the confirmed PR in PDAC replicate across additional patients? A single PR in a dose-escalation cohort is a signal, not proof. Third, do the combination cohorts show additive activity beyond what either drug achieves alone? Pan-KRAS plus cetuximab in colorectal cancer and pan-KRAS plus gemcitabine/nab-paclitaxel in PDAC are the commercially significant combinations. If any combination cohort shows a response rate above the standard-of-care benchmark, BBOT re-rates meaningfully.

The competitive picture: BBOT vs RVMD vs LLY

Revolution Medicines is the clear leader in pan-RAS inhibition. Its daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, delivered a landmark Phase 3 result in May 2026. In the RASolute 302 trial in previously treated metastatic PDAC, daraxonrasib achieved a median overall survival of 13.2 months versus 6.6 months for chemotherapy (HR 0.40, p<0.0001), published in The New England Journal of Medicine. A 60% reduction in mortality in pancreatic cancer, where the 5-year survival rate is 13%, is a result no chemotherapy regimen has matched. RVMD is preparing an NDA submission under the FDA Commissioner’s National Priority Voucher program.

RVMD’s pipeline is also deeper: zoldonrasib (RMC-9805, G12D-selective) has Breakthrough Therapy Designation in NSCLC and showed an 82% ORR combined with chemotherapy in first-line PDAC at ESMO GI 2026. RMC-5127 (G12V-selective) is entering clinical development. At $39.9 billion, RVMD is priced for a multi-product franchise.

Eli Lilly (LLY) has LY4066434, a pan-KRAS inhibitor in Phase 1 (NCT06607185). Lilly’s oncology infrastructure and commercial reach make it a serious competitor, though its program is earlier than both BBOT and RVMD.

BBOT is the smallest and earliest of the three, but BBO-11818’s mechanism (non-covalent, ON and OFF state binding) is differentiated from RVMD’s tri-complex approach (which requires cyclophilin A binding). Whether that mechanistic difference translates to a better clinical profile is the H2 2026 question.

Corporate structure: BBOT is not BBIO

The brief that generated this analysis referenced BridgeBio Pharma (BBIO) as the subject. That is incorrect in a way that matters for investors. BridgeBio Oncology Therapeutics (BBOT) was spun out of BridgeBio Pharma in 2024 with $200 million in private external capital and became a separately traded public company via a SPAC merger with Helix Acquisition Corp II on August 11, 2025. BBIO retained a minority equity stake (approximately 8.99 million shares at nominal cost), but BBOT operates independently with its own management team led by CEO Eli Wallace.

BBIO at $80.09 ($15.7 billion market cap) is a rare disease story driven by Attruby (acoramidis), which generated $180.6 million in Q1 2026 revenue, up 392% year-over-year. BBIO’s BBP-418 LGMD2I PDUFA and encaleret NDA are the thesis for that stock. The pan-KRAS program is a BBOT story, not a BBIO story.

At $648 million, BBOT is pricing BBO-11818 at roughly $600 million in net pipeline value after subtracting the cash from the SPAC transaction. For context, Lumakras at $363 million in annual revenue trades inside Amgen’s $33 billion oncology franchise. If BBO-11818 achieves even $1 billion in peak sales (a fraction of the $5 to $15 billion total addressable market), a 4x revenue multiple implies $4 billion in value, or 6x BBOT’s current market cap. The oncology catalyst calendar ranks pan-KRAS among the highest-impact binary events in the sector.

Risks

The primary risk is that BBOT is 18 months behind RVMD. Daraxonrasib has Phase 3 data, an NDA filing in progress, and four ongoing Phase 3 trials. BBO-11818 is in Phase 1 dose escalation. Even with stellar H2 2026 data, BBOT would need a Phase 3 trial starting in 2027 with readout in 2029 at the earliest. RVMD could capture the first-mover label and set the standard of care before BBOT reaches registration.

The secondary risk is safety. Pan-KRAS inhibitors that hit wild-type RAS carry a theoretical toxicity ceiling. BBO-11818’s selectivity for KRAS over HRAS and NRAS helps, but the DLT-free preliminary data is based on a small number of patients. Dose escalation will test the therapeutic window.

The third risk is dilution. BBOT had $46.2 million in operating expenses in Q1 2026 against a $648 million market cap. The company will need to raise capital to fund Phase 2 and Phase 3 development. At 80 million shares outstanding, further equity raises will dilute existing holders.

Verdict

BBOT at $648 million is a high-risk, high-reward option on pan-KRAS. The preliminary data (confirmed PR in PDAC, no DLTs, dose-proportional exposure covering the key mutations) is genuinely encouraging. The H2 2026 update is the binary catalyst. If the updated Phase 1 shows multiple confirmed responses across tumor types and a clean safety profile at higher doses, BBOT re-rates toward $1.5 to $2 billion, reflecting Phase 2 readiness. If the data is flat or shows dose-limiting toxicity, the stock loses 30 to 50%.

Size this as a small speculative position ahead of the H2 2026 readout, capped at 1 to 2% of a biotech portfolio. The asymmetric payoff justifies the risk, but BBOT is not the stock to hold if you want exposure to the pan-KRAS thesis with lower volatility. For that, RVMD’s daraxonrasib is the safer but more expensive expression. BBOT is the lottery ticket. RVMD is the house.